A representative of UnitedHealth Group Investor Relations confirmed via a direct message with the author that UnitedHealthcare’s coverage of Amarin’s (NASDAQ:AMRN) Vascepa (icosapent ethyl) will continue in 2020 with the same classification as 2019.
Shares up 1% premarket on light volume.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.